Thomas E. Delea

3.0k total citations
136 papers, 2.4k citations indexed

About

Thomas E. Delea is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Thomas E. Delea has authored 136 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 43 papers in Pulmonary and Respiratory Medicine and 32 papers in Economics and Econometrics. Recurrent topics in Thomas E. Delea's work include Health Systems, Economic Evaluations, Quality of Life (19 papers), Bone health and treatments (18 papers) and Hemoglobinopathies and Related Disorders (17 papers). Thomas E. Delea is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (19 papers), Bone health and treatments (18 papers) and Hemoglobinopathies and Related Disorders (17 papers). Thomas E. Delea collaborates with scholars based in United States, United Kingdom and Canada. Thomas E. Delea's co-authors include May Hagiwara, Gerry Oster, John Edelsberg, Oleg Sofrygin, Pradyumna D. Phatak, J. Brandman, Simu K. Thomas, Jennifer Sung, James M. McKiernan and Monika Raut and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

Thomas E. Delea

130 papers receiving 2.3k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Thomas E. Delea	763	529	425	392	378	136	2.4k
Raymond U. Osarogiagbon	845 1.1×	1.6k 3.0×	391 0.9×	535 1.4×	308 0.8×	169	3.1k
Wietske Kievit	408 0.5×	317 0.6×	640 1.5×	413 1.1×	358 0.9×	171	4.1k
Ted Wun	392 0.5×	240 0.5×	684 1.6×	626 1.6×	317 0.8×	75	2.9k
Ulrich Wedding	1.5k 1.9×	808 1.5×	367 0.9×	214 0.5×	429 1.1×	156	3.5k
Laura Giordano	982 1.3×	873 1.7×	201 0.5×	153 0.4×	155 0.4×	165	3.3k
Gregory S. Calip	632 0.8×	204 0.4×	258 0.6×	137 0.3×	202 0.5×	175	2.1k
Dirk Schrijvers	800 1.0×	337 0.6×	771 1.8×	266 0.7×	68 0.2×	62	2.3k
James F. Bishop	1.6k 2.1×	624 1.2×	465 1.1×	134 0.3×	123 0.3×	118	3.0k
Richard S. Ungerleider	756 1.0×	286 0.5×	135 0.3×	102 0.3×	404 1.1×	37	2.3k
Johanneke E.A. Portielje	1.7k 2.2×	571 1.1×	389 0.9×	101 0.3×	280 0.7×	144	3.4k

Countries citing papers authored by Thomas E. Delea

Since Specialization

Citations

This map shows the geographic impact of Thomas E. Delea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Delea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Delea more than expected).

Fields of papers citing papers by Thomas E. Delea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Delea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Delea. The network helps show where Thomas E. Delea may publish in the future.

Co-authorship network of co-authors of Thomas E. Delea

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas E. Delea. A scholar is included among the top collaborators of Thomas E. Delea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas E. Delea. Thomas E. Delea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Waterhouse, David, et al.. (2025). Real-world treatment patterns, healthcare resource utilization, and healthcare costs in patients in the United States with metastatic non-small cell cancer receiving second or subsequent line systemic anticancer therapy. Respiratory Medicine and Research. 88. 101197–101197.

Untch, Michael, David Pérol, Erica L. Mayer, et al.. (2024). Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis. European Journal of Cancer. 202. 113977–113977. 7 indexed citations

Waterhouse, David, et al.. (2024). Real-World Evaluation of Treatment Patterns, Healthcare Costs, and Healthcare Resource Utilization Among Patients with Non-small Cell Lung Cancer in the US Receiving Sotorasib. Advances in Therapy. 41(12). 4648–4659. 3 indexed citations

Thabane, Marroon, et al.. (2020). PCN128 COST-EFFECTIVENESS OF RIBOCILIB PLUS FULVESTRANT (R+F) VS FULVESTRANT (FUL) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE. Value in Health. 23. S45–S45.

Thabane, Marroon, et al.. (2020). PCN87 COST-EFFECTIVENESS OF RIBOCILIB PLUS NONSTEROIDAL AROMATASE INHIBITOR (NSAI) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE. Value in Health. 23. S39–S39.

Jérusalem, Guy, Thomas E. Delea, M. Martín Jiménez, et al.. (2020). 142P Quality-adjusted survival with ribociclib plus fulvestrant (R+F) versus placebo plus fulvestrant (P+F) in postmenopausal women (PMW) HR+/HER2- advanced breast cancer (ABC) based on the MONALEESA-3 trial. Annals of Oncology. 31. S66–S66. 2 indexed citations

Thabane, Marroon, et al.. (2019). PCN87 COST-EFFECTIVNESS ANALYSIS OF DABRAFENIB PLUS TRAMETINIB AS ADJUVANT TREATMENT FOR BRAF V600 MUTATION-POSITIVE MELANOMA AFTER SURGICAL RESECTION IN CANADA- A SOCIETAL PERSPECTIVE. Value in Health. 22. S453–S453. 3 indexed citations

Delea, Thomas E., Derek Weycker, Mark Atwood, et al.. (2017). Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada. PLoS ONE. 12(5). e0175721–e0175721. 13 indexed citations

Thabane, Marroon, et al.. (2014). Cost Effectiveness of Trametinib as First-Line (1l) Treatment for Braf V600 Positive Advanced or Metastatic Melanoma — A Canadian Societal Perspective. Value in Health. 17(3). A83–A83. 3 indexed citations

10.

Delea, Thomas E., et al.. (2014). Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada. PharmacoEconomics. 33(4). 367–380. 18 indexed citations

11.

Hagiwara, May, Thomas E. Delea, Ze Cong, & Karen Chung. (2013). Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer. Supportive Care in Cancer. 22(1). 103–113. 20 indexed citations

12.

Delea, Thomas E., et al.. (2012). PCN70 Cost Effectiveness Analysis Based on Progression Free Survival (PFS) of Pazopanib Versus Sunitinib for the Treatment of Advanced Renal Cell Carcinoma (ARCC) in the Mexican Context. Value in Health. 15(4). A220–A220. 1 indexed citations

13.

Delea, Thomas E., et al.. (2012). PCN123 Retrospective Study of Health Care Utilization and Costs in Women With Metastatic Breast Cancer (MBC) Receiving Lapatinib After Treament With Trastuzumab. Value in Health. 15(4). A230–A230. 1 indexed citations

14.

Delea, Thomas E., Jonathan Karnon, Robert E. Smith, et al.. (2006). Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.. PubMed. 12(7). 374–86. 37 indexed citations

15.

Delea, Thomas E., James M. McKiernan, J. Brandman, et al.. (2006). Impact of Skeletal Complications on Total Medical Care Costs among Patients with Bone Metastases of Lung Cancer. Journal of Thoracic Oncology. 1(6). 571–576. 50 indexed citations

16.

Delea, Thomas E., Richard H. Stanford, May Hagiwara, John Edelsberg, & Gerry Oster. (2004). 821-5 Risks of death and hospitalization in heart failure patients receiving carvedilol versus metoprolol tartrate: A retrospective claims-based study. Journal of the American College of Cardiology. 43(5). A196–A196. 1 indexed citations

17.

Delea, Thomas E., Richard H. Stanford, May Hagiwara, John Edelsberg, & Gerry Oster. (2004). Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate. International Journal of Cardiology. 99(1). 117–124. 13 indexed citations

18.

Delea, Thomas E., May Hagiwara, John Edelsberg, & Gerry Oster. (2002). Exposure to glitazone antidiabetics and risk of heart failure among persons with type 2 diabetes: a retrospective population-based cohort analysis. Journal of the American College of Cardiology. 39. 184–184. 12 indexed citations

19.

Delea, Thomas E., et al.. (1999). Cost effectiveness of carvedilol for heart failure. The American Journal of Cardiology. 83(6). 890–896. 64 indexed citations

20.

Richter, James M., Graham A. Colditz, Daniel M. Huse, Thomas E. Delea, & Gerry Oster. (1989). Cimetidine and adverse reactions: A meta-analysis of randomized clinical trials of short-term therapy☆. The American Journal of Medicine. 87. 278–284. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact